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Background and purpose: To determine appropriate risk-stratification factors for 
prostate cancer patients undergoing stereotactic body radiotherapy (SBRT).
Materials and methods: Between 2006 and 2010, 515 patients with organ-confined 
prostate cancer were treated with a regimen of five-fraction SBRT to dose of 35–36.25 Gy. 
By NCCN criteria, 324 patients were low risk, 153 were intermediate risk, and 38 were 
high risk. Patients were defined as unfavorable intermediate risk if Gleason 4 + 3 = 7 or 
>1 intermediate-risk factors (cT2b, c, PSA 10–20, Gleason 3 + 4 = 7). Cox regression 
analysis was used to determine risk factors significantly associated biochemical failure, 
and patterns of failure analyzed.
results: With median follow-up of 84  months, the 8-year disease-free survival was 
93.6, 84.3, and 65.0% for low, intermediate, and high-risk group patients, respectively. 
Based on the above definition, 106 favorable intermediate-risk patients had excellent 
outcomes, with no significant difference compared to low-risk patients (7-year DFS 95.2 
vs. 93.2%, respectively). The 47 unfavorable intermediate-risk patients had worse out-
comes, similar to high-risk patients (7-year DFS 68.2 vs. 65.0%, respectively). Gleason 
score was the only significant factor associated with biochemical failure on multivariate 
analysis (p = 0.0003).
conclusion: Patients with favorable intermediate-risk disease have excellent outcomes, 
comparable to low-risk patients. Patients with unfavorable intermediate-risk disease 
have significantly worse outcomes after SBRT, and should be considered for clinical 
trials or treatment intensification.
Keywords: prostate cancer, stereotactic body radiotherapy, gleason score, prostate-specific antigen
inTrODUcTiOn
Stereotactic body radiotherapy (SBRT) for organ-confined prostate cancer has increased in accept-
ance over the past few years, as multiple studies continue to emerge demonstrating excellent bio-
chemical control and low toxicity with up to 7-year median follow-up (1–9). Low-, intermediate-, 
and high-risk group stratification is traditionally utilized to assess likelihood of biochemical failure 
after external beam radiation and identify patients who may benefit from systemic therapy (10). 
TaBle 1 | Patient characteristics at diagnosis.
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With this approach, intermediate- and high-risk patients are 
recommended androgen deprivation therapy (ADT) in combina-
tion with standard external beam RT to improve outcomes (11). 
However, it is unclear whether ADT improves outcomes after 
SBRT (8, 9) as published studies suggest that it may not be of 
added benefit in the extreme hypofractionation setting. Tumor 
control mechanisms after high doses per fraction of RT may differ 
compared to standard fractionated RT, due to a distinct radiobio-
logical effect (12). As a result, it is uncertain whether traditional 
risk-stratification criteria are reliable measures for predicting 
outcomes after prostate SBRT. There is a need to explore this 
further, so that patients can be counseled appropriately about the 
risks, benefits, and rationale of prostate SBRT compared to other 
alternatives, and patients predicted to have worse outcomes can 
be directed toward trials incorporating systemic treatments or 
treatment intensification.
The purpose of this study was to determine whether tradi-
tional risk-stratification criteria remain relevant for predicting 
outcomes after SBRT. With the longest follow-up to date of 
any single institution series, we now identify characteristics of 
patients expected to have excellent outcomes after SBRT vs. those 
who remain at higher risk of biochemical failure, who may benefit 
from either treatment intensification and/or systemic therapies.
MaTerials anD MeThODs
Patient selection
The study cohort was composed of 515 men with biopsy-proven, 
newly diagnosed non-metastatic prostate cancer, treated as per an 
IRB-approved protocol between early 2006 and late 2009. Patient 
characteristics are summarized in Table 1. For the purposes of 
this analysis, patients were stratified using standard risk catego-
ries (11) of low risk (n = 324) (PSA <10 and Gleason sum of 6 and 
clinical stage T1c–T2a); intermediate risk (n = 153) (PSA 10–20, 
Gleason sum of 7 or clinical stage T2b, c); and high risk (n = 38) 
(PSA >20, Gleason 8–10 or T3a–T4). NCCN 1.2016 guidelines 
suggest further stratification of patients into unfavorable inter-
mediate risk if they have Gleason 4 + 3 = 7 disease, >50% positive 
cores or >1 intermediate-risk factors; using this definition, there 
were 106 patients with favorable and 47 patients with unfavorable 
intermediate-risk disease. Mean patient age at time of treatment 
was 68 years (range, 43–88). A total of 72 patients received up to 
6 months of ADT prior to and during treatment, at the discretion 
of the urologist. The median PSA at diagnosis was 6.6 ng/mL.
Treatment
Fiducial-based image-guided SBRT was delivered using the 
CyberKnife system (Accuray Inc., Sunnyvale, CA, USA). The 
treatment specifics of Cyberknife have been published previ-
ously (13). General techniques are briefly outlined here. Four 
gold fiducials were placed in the prostate trans-perineally with 
ultrasound guidance. This was followed by a non-contrast CT 
scan in the supine position and in an alpha cradle. Except for 
those patients that could not undergo an MRI scan, MRI images 
were obtained and fused into the CT images to better visualize the 
inferior portion of the prostate. No catheter was used. Anatomical 
contours of the prostate, seminal vesicles, rectum, bladder, penile 
bulb, femoral heads, and testes were generated. With homogene-
ous planning, dose was prescribed to the planning target volume 
(PTV) that consisted of a volumetric expansion of the prostate 
by 5 mm, reduced to 3 mm in the posterior direction. During a 
typical 45-min treatment, fiducial seeds were tracked and adjust-
ments to position were made at 30–60 s intervals. For each morn-
ing prior to SBRT, patients underwent a bowel prep including 
Dulcolax® (Boehringer Ingelheim, Germany) and a Fleet® Enema 
(C.B. Fleet Company, Inc., Lynchburg, VA, USA). In addition, at 
least 15–20 min before treatment, all patients received 1500 mg of 
amifostine (MedImmune, LLC Gaithersburg, MD, USA), mixed 
in saline, and instilled into the rectum. The dose of radiotherapy 
consisted of either 35 or 36.25 Gy over five fractions, given daily 
for all patients.
Dose was normalized to the 83–87% isodose line in order for 
the prescription dose to cover at least 95% of the PTV. Generally 
speaking, dose volume histogram (DVH) goals for the rectum were 
such that the V50% <50% (i.e., the volume receiving 50% of the 
TaBle 2 | Patient characteristics of unfavorable-intermediate and high-
risk patients at diagnosis.
entire cohort Unfavorable int high
# % # % # %
age
40–49 2 1.2 1 2.1 0 0
50–59 5 5.9 2 4.3 3 8
60–69 26 30.6 13 27.6 13 34
70–79 38 44.7 24 51.1 14 37
80–89 15 17.6 7 14.9 8 21
Total 85 47 38
Mean (range) 71.1 (43–88) 71 (43–88) 71 (51–86)
Psa level at treatment
Mean 10.8 (SD = 8.5) 7.6 14.8
Median  8.8 7 10.1
Psa level at diagnosis
<4 ng/mL 12 14.1 8 17 4 10.5
4–10 ng/mL 37 43.5 24 51.1 13 34.2
>10 ng/mL 36 42.4 15 31.9 21 55.3
clinical stage
T1c 66 89.7 38 80.8 28 73.6
T2a 19 10 9 19.2 10 26.4
gleason score
6 3 3.5 0 0 3 7.9
7 (3 + 4) 8 9.4 7 14.9 1 2.6
7 (4 + 3) 42 49.4 40 85.1 2 5.3
8 (4 + 4) 24 28.2 0 0 24 63.2
9 (4 + 5) 6 7 0 0 6 15.8
9 (5 + 4) 2 0.2 0 0 2 5.3
hormone treatment
No 52 61.1 35 74.5 17 44.7
Yes 33 38.8 12 25.5 21 55.3
Dose 35 Gy 11 12.9 7 15 4 10.5
36.25 Gy 74 87.1 40 85 34 89.5
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prescribed dose was <50%), V80% <20%, V90% <10%, and V100% 
<5%. The bladder DVH goals were V50% <40% and V100% <10%. 
For the bladder and the rectum, a typical D50 was 40–45% of the 
maximum dose. The femoral head DVH goal was V40% <5%.
Follow-up and Toxicity assessment
The median follow-up for the entire cohort was 84 months (inter-
quartile range, 60–96 months). In general, PSAs were obtained at 
baseline, and prospectively at 3 months post-treatment intervals 
during the first 2 years and at 6 months intervals thereafter. The 
PSA relapse definition used was the currently adopted standard 
of care Phoenix definition (i.e., nadir +2) (14). Biochemical 
disease-free survival (bDFS or PSA DFS) was calculated with the 
Kaplan–Meier method and differences between groups deter-
mined by the log-rank test. Quality of life (QOL) was assessed 
using the Expanded Prostate Cancer Index Composite (EPIC) 
questionnaire (15) at every follow-up visit during the first year 
and at 24 months. EPIC scores were calculated as defined in Wei 
et al. (15). In addition, toxicity was assessed using the Radiation 
Therapy Oncology Group (RTOG) urinary and rectal toxicity 
scale (16) at every follow-up visit. QOL and toxicity data have 
been reported previously (7, 8).
For patterns of failure, a prostate biopsy showing positive 
disease, in the absence of metastatic disease, was counted as a 
local failure, independent of distant failure status. Biopsy-proven 
evidence of metastatic disease, or imaging characteristics consist-
ent with widespread metastatic disease attributable to prostate 
cancer, was counted as distant failure.
statistical analysis
The primary endpoint of the study was bDFS. Kaplan–Meier sur-
vival method was used to estimate bDFS and log-rank p-values 
were used to compare the distributions. Cox regression analysis 
was used to determine whether risk factors were significant after 
adjusting for competing risks. For Cox regression analysis, the 
assumption of the proportional hazards model was tested to ensure 
that these assumptions were not violated. The pretreatment PSA 
and Gleason score were treated as dichotomous variables, using a 
cutpoint of 5.4 ng/μL (median value) for PSA and Gleason score 
<8 vs. ≥8. Two-sided p < 0.05 was considered to be statistically 
significant. The likelihood ratio test was used to determine if there 
was significant difference in toxicity. JMP Pro 10 (SAS Institute, 
Cary, NC, USA) was used for statistical analyses.
resUlTs
Biochemical Disease-Free survival
Median follow-up was 84 months (range, 6–108 months). At last 
follow-up, 83 patients were deceased from non-prostate cancer-
related causes. Patient characteristics are detailed in Tables  1 
and 2. The actuarial 8-year bDFS was 93.6, 84.3, and 65.0% for 
low-, intermediate-, and high-risk group patients (Figure  1). 
Per NCCN 1.2016, patients with two or more adverse factors 
(T2b–T2c, Gleason score = 7, PSA 10–20 ng/mL), >50% posi-
tive cores or Gleason 4 + 3 = 7 can be considered as unfavorable 
intermediate risk. We repeated our analyses, therefore, using 
these risk-stratification criteria (Figure 2), and found low- and 
favorable intermediate-risk patients to have similar bDFS (7-year 
DFS 95.2 vs. 93.2%, respectively, p < 0.0001).
Unfavorable intermediate-risk patients performed signifi-
cantly worse, with outcomes similar to high-risk patients (7-year 
DFS 68.2 vs. 65.0%, respectively; p <  0.0001). To analyze this 
further (Figure  3), unfavorable intermediate-risk patients with 
Gleason 4 + 3 = 7 or >1 intermediate-risk factor were compared 
to high-risk patients, and no significant differences were noted 
(5-year DFS 85.5, 70.0, and 68.6%, respectively; p = 0.49).
sBrT Dose Does not impact  
Biochemical Disease-Free survival
Patients were treated to either 35 or 36.25 Gy in five consecutive 
daily fractions. Given that favorable intermediate-risk patients 
performed as well as low-risk patients, we combined both groups 
prior to performing our analysis and found no significant differ-
ence in biochemical outcome as a function of SBRT dose (Figure 4) 
(9-year DFS 95.3 vs. 93.5% for 35 vs. 36.25 Gy, p = 0.67). A similar 
analysis was performed for unfavorable intermediate-risk and 
high-risk patients, and again we found no difference in outcome 
as a function of SBRT dose.
FigUre 4 | Biochemical disease-free survival stratified by dose. bDFS 
in low- and favorable intermediate-risk patients. With follow-up up to 9 years, 
we find no significant difference by dose.
FigUre 3 | Biochemical disease-free survival of high-risk and 
unfavorable intermediate-risk patients with either gleason 4 + 3 = 7, 
or >1 risk factors, shows no significant difference.
FigUre 2 | Biochemical disease-free survival with intermediate-risk 
group further stratified into favorable vs. unfavorable risk. There was 
no significant difference between the low- and favorable intermediate-risk 
group with follow-up of 9 years. There was a significant (p < 0.0001) 
difference between the low- and favorable intermediate-risk group vs. the 
unfavorable intermediate-risk and high-risk patients.
FigUre 1 | Biochemical disease-free survival stratified into low-, 
intermediate-, and high risk (as defined by nccn).
TaBle 3 | relative risk and p-value from cox regression multivariable 
analysis for pretreatment predictors of biochemical failure.
Pretreatment variable risk (95% ci) p-Value
Hormones (no vs. yes) 1.08 (0.48–2.29) 0.84
Dose (35 vs. 36.25 Gy) 1.53 (0.74–3.6) 0.26
Gleason score (≤7, ≥8) 6.34 (2.74–13.83) <0.0001
PSA (≤5.4 ng/ul, >5.4 ng/ul) 1.45 (0.79–2.70) 0.22
CI, confidence interval; Gy, Gray.
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risk Factors for Biochemical  
Failure after Prostate sBrT
Results of Cox multivariable regression analysis are shown 
in Table  3. Pretreatment factors included in the analyses were 
use of ADT, baseline PSA, Gleason score, and dose. The only 
variable found to be significant as a predictor for biochemical 
failure was Gleason score, which is a known prognostic factor 
(p < 0.0001). Use of ADT in the unfavorable-intermediate and 
high-risk patient was analyzed separately, and there was no 
statistically significant difference (p > 0.05).
5Katz et al. Risk Stratification after Prostate SBRT
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Patterns of Failure after Prostate sBrT
Crude percentages of PSA, local and distant failure for low, 
favorable intermediate-risk, unfavorable intermediate-risk, 
and high-risk patients are shown in Figure  5. The median 
time to each type of failure is graphically depicted in Figure 6. 
Patients in the unfavorable intermediate-risk and high-risk 
category had a shorter median time to distant failure compared 
to patients in the low- and favorable intermediate-risk category 
(15.5 and 18  months vs. 42 and 55  months, respectively, 
p < 0.05). Patients in the high-risk category had a significantly 
shorter median time to biochemical (18 vs. 51  months) and 
local failure (9 vs. 66  months) compared to the other risk 
groups.
DiscUssiOn
Our study, with the longest follow-up to date of any single 
institution series that has been reported, suggests that traditional 
risk-stratification criteria can be simplified to predict outcomes 
after SBRT. Patients with Gleason score of 3 + 4 with PSA <10, 
or Gleason 3 + 3 with PSA 10–20, are historically classified as 
intermediate-risk. However, in our dataset with up to 9  years 
of follow-up, we find no significant difference in bDFS between 
this favorable intermediate-risk group and low-risk patients. 
Both local and distant relapse rates remain ≤2% after a dose 
to 35 or 36.25 Gy in five fractions, suggesting that further dose 
escalation or systemic treatment will not be of significant benefit. 
FigUre 5 | Failure patterns after prostate sBrT: type of failure. % PSA, local and distant failure stratified by risk group. All cases of local failure were proven 
on biopsy. Distant failure was biopsy proven, unless widespread metastatic disease on imaging.
FigUre 6 | Failure patterns after prostate sBrT: time to failure. Median time to PSA, local and distant failure subdivided by risk group.
6Katz et al. Risk Stratification after Prostate SBRT
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This brings into question ongoing dose-escalation protocols for 
low and intermediate-risk prostate cancer patients, which may 
be needlessly placing patients at risk of higher toxicity without 
providing meaningful local control benefit.
In this study, unfavorable intermediate-risk patients fared no 
better than high-risk patients. On multivariate analysis, Gleason 
score was the only factor significant for bDFS, suggesting that 
primary Gleason score is a driving force behind prostate cancer 
outcomes after SBRT. This is consistent with multiple studies 
demonstrating the relevance of Gleason score as a prognostic fac-
tor across all treatments for prostate cancer (17, 18). Use of ADT 
or higher dose did not have a significant impact on outcomes, 
consistent with emerging literature, suggesting that ADT may be 
of limited benefit in combination with SBRT (8). Consistently, a 
BED equivalent of 200 Gy (equivalent of 35–36.25 Gy assuming 
α/β of 1.5) has been suggested as the maximum dose beyond 
which there are no improvements in disease control, but only 
added toxicity (19).
Our results for intermediate- and high-risk patients are 
comparable to those achieved with IMRT and other modalities, 
and support use of SBRT as a treatment alternative in this patient 
population. In our study, the predominant pattern of failure is 
biochemical and/or distant. As such, PSA failures likely represent 
undetectable micrometastatic disease already present at the time 
of diagnosis and initial treatment. Given this scenario, dose esca-
lation to the prostate alone is unlikely to be of substantial benefit, 
while a combination strategy incorporating systemic treatment 
into the SBRT treatment paradigm may be better suited to com-
bat distant spread. Hopefully, future trials with novel treatment 
strategies will focus on this subgroup of patients.
Several limitations of our study include lack of information on 
% positive cores, relatively small numbers for high-risk patients, 
and the single institution nature of the trial. Also, the use of ADT 
in a subset of patients at the urologist’s discretion was not found to 
be significant for bDFS, but nevertheless complicates the analysis. 
Despite these limitations, given that prostate SBRT is a newly 
emerging technique with minimal data on long-term outcomes, 
we believe our present work will be hypothesis generating and of 
use to radiation oncologists, until data from larger prospective 
studies become available.
In summary, SBRT to well-tolerated total doses of 35–36.35 Gy 
in five fractions continues to show excellent biochemical and 
local control with up to 9 years of follow-up. A significant bDFS 
difference exists for favorable vs. unfavorable intermediate-risk 
groups, suggesting that a simple risk-stratification construct of 
lower vs. higher-risk can be utilized to discuss risks of failure 
when patients consider prostate SBRT, until data from current 
prospective studies mature. While still requiring confirmation by 
additional prospective trials, patients with Gleason score of 3 + 4 
with PSA <10, or Gleason 3 +  3 with PSA 10–20 who would 
traditionally have been classified as intermediate risk, had excel-
lent outcomes in this study, no different from low-risk patients, 
and may not require dose escalation or consideration of ADT.
The remaining challenge is how to improve outcomes for 
patients with unfavorable intermediate-risk and high-risk dis-
ease, who remain at high risk of distant failure. In this subset, 
combination treatment or novel therapies are warranted for clini-
cal trials testing. To our knowledge, this series provides clinical 
results with the longest follow-up reported, supporting existing 
guidelines that incorporate prostate SBRT into the treatment 
paradigm for low- and intermediate-risk patients.
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